Veterinary Pain Management Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Medications, Medical Devices), By Application (Joint Pain, Cancer Pain, Postoperative Pain, Others), By Animal Type (Companion Animal, Livestock Animal), By Region and Competition, 2020-2030F

Market Overview

Global Veterinary Pain Management Market was valued at USD 2.94 billion in 2024 and is expected to reach USD 4.34 billion by 2030 with a CAGR of 6.71% during the forecast period. The global market for Veterinary Pain Management is experiencing significant growth, driven by the growing incidence of inflammatory and painful diseases such as deficiency disease, hereditary diseases, and physiological diseases in the animal population. Additionally, growing the need for easily accessible and affordable treatment procedures in the urban regions and growing awareness about animal health and welfare have significantly enhanced the demand for veterinary pain management across different parts of the globe.

Key Market Drivers

Increasing Pet Ownership and Companion Animal Expenditures

The rising rate of pet ownership worldwide, particularly in developing and developed countries, is a significant driver for the veterinary pain management market. Pet animals, particularly dogs and cats, are increasingly being treated as family members, leading to greater attention toward their health and well-being, including effective pain management for both chronic and acute conditions.

According to the American Pet Products Association (APPA), around 66% of U.S. households, or approximately 86.9 million homes, owned a pet as of 2023. This rose from about 56% in 1988. Similar trends are being observed in countries like China, Brazil, and India, where urbanization and increasing disposable incomes are contributing to higher pet adoption rates. The USDA's Animal and Plant Health Inspection Service (APHIS) supports this through programs that focus on the humane care and management of animals, reflecting a broader global awareness of animal welfare.

Spending on veterinary care has also increased in tandem. The APPA reported that U.S. consumers spent over $38.3 billion on veterinary care and product sales in 2023 alone. A significant share of this expenditure goes toward pain relief medications, especially in cases of surgery, injury, arthritis, or cancer in pets. Furthermore, the human-animal bond has become a central component in shaping veterinary healthcare policies, prompting governments and organizations to invest in veterinary infrastructure and awareness campaigns about animal health, including pain mitigation.

Growth in Livestock Production and Animal Welfare Regulations

The growth of the global livestock industry, driven by the increasing demand for meat, dairy, and other animal-based products, has intensified the need for better pain management practices in food-producing animals. Modern agricultural practices now recognize the ethical and productivity implications of managing pain in livestock during surgeries, injuries, lameness, and common procedures like castration or dehorning.

According to the Food and Agriculture Organization (FAO) of the United Nations, global meat production reached 364 million tonnes in 2023, driven largely by demand in Asia and Latin America. To meet this demand sustainably and ethically, pain management is becoming a focal point of animal husbandry. Governments across several regions have started to enforce more stringent animal welfare standards. For instance, the European Union's Directive 98/58/EC sets requirements for minimizing pain and suffering in farm animals, including mandatory use of anesthetics and analgesics during painful procedures.

In countries like Australia and New Zealand, the national animal welfare standards mandate the use of pain relief for various livestock practices. For example, the Australian Animal Welfare Standards and Guidelines for Cattle stipulate the use of analgesia for procedures like spaying and dehorning. The U.S. Department of Agriculture (USDA) also supports research and educational programs under its Animal Welfare Act to promote humane treatment in livestock. These regulatory developments are compelling livestock producers to adopt veterinary pain management solutions. The push toward “humanely raised” certifications also influence consumer preferences, further encouraging farmers to integrate pain management into their animal care protocols. Consequently, this regulatory and ethical landscape acts as a major driver for market growth.

Download Free Sample Report

Key Market Challenges

Limited Access to Veterinary Pain Management in Rural and Low-Income Regions

A critical challenge faced by the global veterinary pain management market is the limited accessibility of services and medications in rural and low-income regions. Veterinary infrastructure in such areas often lacks adequately trained professionals, pain-relief medications, diagnostic equipment, and awareness about the necessity of pain management, especially for livestock and working animals. In low- and middle-income countries (LMICs), veterinary care is largely reactive rather than preventive or therapeutic. According to the World Organisation for Animal Health (WOAH, formerly OIE), over 45% of countries surveyed lack sufficient veterinary service coverage in rural areas, with inadequate financial resources to ensure widespread availability of analgesics and pain-relieving procedures. The disparity is particularly acute in sub-Saharan Africa, South Asia, and parts of Latin America, where veterinarians per capita are far below global standards. Additionally, pain in animals is often under-recognized or normalized due to cultural attitudes or lack of training, reducing demand for pain-relieving interventions. This is further compounded by the unavailability or high cost of approved drugs. For instance, multimodal analgesic regimens or advanced therapies like laser treatment are often not economically viable for livestock farmers in these regions. Government animal health budgets in many LMICs focus more on disease control and food safety rather than pain management. For example, a FAO report highlighted that in several African nations, only 0.03% to 0.1% of the national health budget is allocated to veterinary services, with minimal attention to pain relief.

Regulatory Hurdles and Concerns Over Drug Residues in Food-Producing Animals

Another major challenge facing the veterinary pain management market is the complex regulatory environment governing the use of analgesics in food-producing animals. Ensuring that animals do not experience unnecessary pain while also complying with stringent food safety standards presents a significant conundrum. The use of non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and local anesthetics in cattle, swine, and poultry is heavily regulated due to concerns over drug residues entering the human food chain. Regulatory bodies such as the U.S. FDA, the European Medicines Agency (EMA), and the Codex Alimentarius Commission have set maximum residue limits (MRLs) for veterinary drugs. These limits are designed to ensure that meat, milk, and eggs are safe for human consumption. However, the complex withdrawal periods, residue monitoring requirements, and pharmacokinetic data demands make the approval process lengthy and expensive for pharmaceutical companies. As a result, relatively few pain medications are approved for use in livestock.

In the U.S., the FDA’s Center for Veterinary Medicine (CVM) has approved only a handful of drugs for pain management in food animals, and many treatments are used off-label under veterinary supervision. Similar restrictions apply in Canada, the EU, and Australia. Additionally, the lack of harmonized international regulations creates challenges for livestock producers engaged in global trade.

Key Market Trends

Advancements in Drug Delivery Systems and Non-Invasive Therapies

The veterinary sector is witnessing a surge in innovative drug delivery systems and non-invasive therapies aimed at improving the efficacy and compliance of pain management solutions. Traditional oral or injectable medications, while effective, often come with challenges such as stress during administration, the need for repeated dosing, and potential side effects. As a result, there is a growing shift toward transdermal patches, long-acting injectables, chewable medications, and even wearable devices. One notable advancement is the development of sustained-release formulations, which ensure prolonged therapeutic effects and reduce the frequency of administration. These systems are particularly beneficial in managing chronic pain conditions such as osteoarthritis or post-operative pain. Moreover, technologies such as transdermal drug delivery — which allows medication to be absorbed through the skin — are gaining traction. This approach is not only stress-free for the animal but also safer for the owner or veterinarian administering it.

In addition to pharmacological methods, non-invasive therapies like cold laser therapy, pulsed electromagnetic field therapy (PEMF), and acupuncture are being increasingly adopted. These approaches reduce dependency on drugs, especially opioids, and appeal to pet owners concerned about side effects or long-term drug use. Government-supported veterinary research initiatives are contributing to the evolution of these technologies. For instance, the U.S. National Institutes of Health (NIH) funds collaborative research into veterinary pharmacology and pain management tools. Similarly, countries like Canada and the UK have government-supported veterinary innovation programs fostering the development of novel delivery systems.

Growing Integration of Telehealth and Digital Monitoring Tools in Pain Assessment

Veterinary telemedicine is emerging as a transformative trend in pain management, enabling remote assessment, diagnosis, and monitoring of pain in animals, especially in rural or underserved areas. The COVID-19 pandemic accelerated the adoption of telehealth across human and animal healthcare, and the trend has continued, particularly in follow-up consultations, pain reassessments, and medication management. Digital monitoring tools, such as wearable sensors and smartphone-based applications, are being integrated with telehealth services to enable real-time tracking of an animal’s physiological and behavioral data. Devices capable of monitoring vital signs, movement, or posture can help veterinarians and pet owners assess whether an animal is in pain or recovering adequately after treatment. For example, wearable activity monitors can detect signs of lameness or decreased mobility, key indicators of chronic pain in dogs or horses.

According to a 2022 report from the U.S. Food and Drug Administration (FDA), digital health tools in veterinary settings are gaining traction and are part of ongoing regulatory discussions. The European Medicines Agency (EMA) has also acknowledged the potential of digital innovations in veterinary pharmacovigilance and treatment monitoring. This digital transformation allows for continuous, data-driven pain management, ensuring more personalized care and faster interventions. It also facilitates better compliance, as reminders for medication or behavior tracking can be shared with pet owners via mobile apps.

Segmental Insights

Product Insights

Based on Product, Medications category currently hold the largest market share. This dominance is largely attributed to the widespread use of pharmacological interventions as the first-line approach in both acute and chronic pain scenarios across companion and livestock animals. Factors such as ease of administration, cost-effectiveness, well-established regulatory approvals, and availability of a wide range of drug classes contribute to the segment’s market leadership. Veterinary medications used for pain management are primarily divided into non-steroidal anti-inflammatory drugs (NSAIDs), opioids, local anesthetics, corticosteroids, and adjunctive drugs such as gabapentin or amantadine. NSAIDs remain the most frequently prescribed category for pain associated with musculoskeletal disorders, injuries, and post-surgical recovery. For instance, drugs such as carprofen, meloxicam, and firocoxib are routinely used in dogs and horses for their anti-inflammatory and analgesic effects. The U.S. Food and Drug Administration (FDA), through its Center for Veterinary Medicine (CVM), has approved several such medications specifically for veterinary use, reflecting a strong regulatory framework that facilitates product adoption.

Download Free Sample Report

Regional Insights

Based on the region, North America has emerged as the leading regional market in the global veterinary pain management sector, driven by a combination of advanced veterinary infrastructure, high pet ownership rates, proactive animal welfare legislation, and increased expenditure on companion and livestock animal health. One of the primary reasons for North America's dominance is the high prevalence of pet ownership. According to the American Pet Products Association (APPA), approximately 66% of U.S. households, equating to nearly 86.9 million homes, owned at least one pet in 2023. Similarly, pet ownership in Canada remains strong, with the Canadian Animal Health Institute (CAHI) reporting that over 60% of Canadian households own pets, primarily dogs and cats. These demographics contribute significantly to veterinary visits, especially for pain-related issues stemming from conditions like arthritis, injury, and post-operative recovery. Moreover, spending on veterinary care is significantly higher in North America than in other regions. U.S. consumers spent an estimated $38.3 billion on veterinary services and products in 2023, as per the APPA. A substantial portion of this spending goes toward diagnostics, pain relief therapies, and advanced treatment options including laser therapy, physical rehabilitation, and innovative drug formulations such as long acting injectables or transdermal patches.

Recent Developments

• In September 2024, Boehringer Ingelheim announced the acquisition of Saiba Animal Health AG, a company focused on developing innovative therapeutic treatments for chronic diseases in dogs.
• In July 2024, Merck Animal Health completed the acquisition of the aqua division of Elanco Animal Health Incorporated, enhancing its position in the aquatic animal health sector.
• In March 2024, Zoetis strengthened its footprint in Australia by acquiring a 21-acre manufacturing facility in Melbourne. This strategic move is aimed at expanding its operational capacity and boosting future production of vaccines for a range of animals, including sheep, cattle, dogs, cats, and horses.
• In February 2024, EQT, a Swedish investment firm, acquired Dechra Pharmaceuticals, a prominent manufacturer of veterinary pharmaceuticals.

Key Market Players

• Boehringer Ingelheim International GmbH
• Zoetis Inc.
• Elanco Animal Health Incorporated
• Norbrook Laboratories Limited
• SeQuent Scientific Limited
• Merck & Co., Inc.
• Dechra Pharmaceuticals Plc
• Vetoquinol S.A.
• Ceva Santé Animale SA
• Chanelle Pharma Group Ltd

Report Scope:

In this report, the Global Veterinary Pain Management Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Veterinary Pain Management Market, By Product:

o   Medications

o   Medical Devices

• Veterinary Pain Management Market, By Application:

o   Joint Pain

o   Cancer Pain

o   Postoperative Pain

o   Others

• Veterinary Pain Management Market, By Animal Type:

o   Companion Animal

o   Livestock Animal

• Veterinary Pain Management Market, By Region:

o   North America

§  United States

§  Mexico

§  Canada

o   Europe

§  France

§  Germany

§  United Kingdom

§  Italy

§  Spain

o   Asia-Pacific

§  China

§  India

§  South Korea

§  Japan

§  Australia

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East and Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Veterinary Pain Management Market.

Available Customizations:

Global Veterinary Pain Management Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Veterinary Pain Management Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]